Results 211 to 220 of about 122,145 (339)

Semaglutide 2.4 mg Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States (SMILE)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the real‐world associations between semaglutide 2.4 mg and cardiometabolic comorbidities, biomarkers and cardiovascular risk among adults with overweight or obesity. Methods This retrospective cohort study used US claims data and laboratory measurements from the Komodo Research Database (2016–2024). Adults with obesity or with
Aleksandrina Ruseva, Wojciech Michalak, Matthew Bassan, Ella Xiaoyan Du, Anthony Fabricatore, Bríain Ó Hartaigh, Theo Man, Ramya Ramasubramanian, Pangsibo Shen, Jinlin Song, Zhenxiang Zhao, Francisco Lopez‐Jimenez   +11 more
wiley   +1 more source

Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP‐1 Receptor Agonists: A Meta‐Analysis and Meta‐Regression of Randomised Controlled Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine whether on‐treatment changes in kidney function and cardiometabolic markers are associated with the magnitude of heart failure (HF) risk reduction across large‐scale trials of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs).
Masashi Hasebe, Hisashi Kamido, Chen‐Yang Su, Yamato Keidai, Daisuke Yabe, Satoshi Yoshiji   +5 more
wiley   +1 more source

Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov. [PDF]

Addict Behav Rep
Patil S, Jha N, Jha MK.
europepmc   +1 more source

Emerging role of insulin with incretin therapies for management of type 2 diabetes [PDF]

, 2011
Rupa Ahluwalia, Jiten Vora
core   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

Risk of peripheral vestibular disorders and hearing impairment among users of glucagon-like peptide-1 receptor agonists. [PDF]

Int J Med Sci
Huang JY, Lu YT, Hsin CH, Lo TS, Lee CY, Yang SF, Liao MY.   +6 more
europepmc   +1 more source

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Geremia B. Bolli, Philip D. Home, Mauro Lepore, Matthew C. Riddle, Francesca Porcellati, Carmine G. Fanelli, Paola Lucidi, Hannele Yki‐Järvinen, Reinhard H. Becker, David R. Owens   +9 more
wiley   +1 more source

Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases. [PDF]

Arthritis Rheumatol
Karacabeyli D, Lacaille D, Lu N, Xie H, Aviña-Zubieta JA.   +4 more
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Petrelintide is a long‐acting amylin analogue in development for weight management. The safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide were evaluated in single ascending dose (SAD) and multiple ascending dose (MAD) trials. Materials and Methods Both trials were randomized, placebo‐controlled, and double‐blind.
Minna Brændholt Olsen, Jon Griffin, Ulrike Hövelmann, Stanislava Macura, Berith Fredsted Hagen, Dan Hesse, Tim Heise   +6 more
wiley   +1 more source

The Influence of Glucagon-like Peptide-1 Receptor Agonists on Outcomes Following Trigger Finger Release. [PDF]

J Hand Surg Glob Online
Dameron LS, Bank NC, Raghava N, Himmelberg S, Knoll GM.   +4 more
europepmc   +1 more source